Drug Development ProgressAdvancing to Enhertu’s filing for 1L HER2+ BC with strong DB09 interim data shows promising progress in drug development.
FDA ApprovalsFDA has approved anticancer candidate Dato-DXd for breast cancer, which is considered a positive surprise by the market.
Share BuybackA recent JPY200Bn-buyback was conducted in defiance of the weak stock price, indicating confidence in the company's corporate value.
Upcoming ApprovalsProspects for Dato's approval for 2L EFGR+ NSCLC seem good, which could help stabilize and rebound the stock.